ABL-103
- Generic Name
- ABL-103
A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06126666
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Seoul, Korea, Republic of
🇰🇷Sevrance Hospital, Seoul, South Korea, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath